Power Law company profile

KalVista Pharmaceuticals

Biotech & Life Sciences · Cambridge, United States · Founded 2011 · IPO 2016 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$1.27B

Market cap · May/2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Oral small-molecule protease inhibitors for rare diseases

Investors

7 investors on KalVista Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 3 investors entered at this stage

Novo Seeds

Novo Holdings

SV Health Investors

Series B+ 4 investors entered at this stage

RA Capital Management

Venrock

University of Utah

Longwood Fund

Global footprint

Where KalVista Pharmaceuticals has talent and traffic

Web traffic by country

10K monthly visits
across markets

🇺🇸 United States53%

🇮🇳 India24%

🇵🇭 Philippines10%

🇬🇧 United Kingdom7%

🇩🇪 Germany7%

Top 5 markets shown

Sentiment on X

What X is saying about KalVista Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about KalVista Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See KalVista Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo